NNV1 is under clinical development by TheraBiologics and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how NNV1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NNV1 overview

NNV1 is under development for the treatment of recurrent glioblastoma multiforme (GBM), anaplastic astrocytoma, gliosarcoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma and high-grade glioma. The therapeutic candidate comprises immortalized neural stem cells (NSC) loaded with oncolytic adenovirus (CRAd-S-pk7). It is administered through intracerebral route and is being developed based on NeuroNova platform.

It was also under development for the treatment of malignant glioma.

TheraBiologics overview

TheraBiologics (TBX) is a clinical-stage bio pharmaceutical company which develops human neural stem cell (NSC)-mediated cancer therapies. It lead product candidates include TBX.OncV, a cancer gene therapy product which produce oncolytic adenovirus targeting multiple heterogeneous tumors, that replicate tumor cells, and does not affect normal cells; TBX.CE, an enzyme or prodrug gene therapy product that activates the prodrug irinotecan to chemotherapeutic drug against metastatic neuroblastoma. The company’s TBX NSC platform is engineered to deliver a range of anti-cancer agents targeting invasive cancers which enable to maximize therapeutic concentrations at the tumor sites and minimize off target toxicities. TBX is headquartered in Arcadia, California, the US.

For a complete picture of NNV1’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 7 February 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.